^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GSPT1 deletion

    i
    Other names: GSPT1, G1 To S Phase Transition 1, Eukaryotic Peptide Chain Release Factor GTP-Binding Subunit ERF3A, Eukaryotic Peptide Chain Release Factor Subunit 3a, G1 To S Phase Transition Protein 1 Homolog, Eukaryotic Release Factor 3a, ERF3a, 551G9.2, ETF3A, ERF3A, GST1
    Entrez ID:
    2935
    1year
    MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling. (PubMed, Mol Cancer Ther)
    A MIG6 deletion was also found in a patient after progressing to ROS1 inhibition. Collectively, this study identifies MIG6 as a novel regulator for EGFR-mediated adaptive and acquired resistance to ALK/ROS1 inhibitors and suggests EGFR to MIG6 ratios and MIG6 damaging alterations as biomarkers to predict responsiveness to ALK/ROS1 and EGFR inhibitors.
    Preclinical • Journal
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ERRFI1 (ERBB Receptor Feedback Inhibitor 1)
    |
    EGFR mutation • ALK mutation • ROS1 fusion • GSPT1 deletion • ALK-ROS1 fusion • ERRFI1 deletion